Summary of Swedish Orphan Biovitrum (Sobi) Capital Markets Day 2026 Company Overview - **Company**: Swedish Orphan Biovitrum (Sobi) - **Event**: Capital Markets Day 2026 - **Date**: February 18, 2026 - **Focus**: Progression of the company, development pipeline, and strategic outlook towards 2030 [1][2] Key Points Strategic Outlook - Sobi is transitioning from a focus on hemophilia to a more diversified portfolio, with significant growth in various therapeutic areas [4][5] - The company aims to double its size by 2030, building on a foundation of six major product launches planned by 2028 [24][43] - Sobi has achieved significant EBITDA growth and nearly doubled its business over the last five years, indicating strong operational resilience [8][9] Product Pipeline and Launches - **Current Products**: - Altuviiio (hemophilia A) - Gamifant (HLH) - Aspaveli (nephrology) - Tringalza (FCS) - **Upcoming Launches**: - NASP (uncontrolled gout) expected mid-year - Tringalza in SHDG, already launched in Germany and Austria - Posotenurad (gout) anticipated with the acquisition of Arthrosie Therapeutics [20][21][30][31] Therapeutic Areas - **Gout**: Sobi has two products in this area, with a focus on addressing high unmet medical needs [19][20] - **Sepsis**: The company is exploring interferon gamma-driven sepsis, which affects a significant patient cohort [36][37] - **Chronic Synovitis**: Sobi aims to improve joint health in hemophilia patients, addressing chronic complications through clinical trials [56][57] Market Expansion - Sobi has expanded its global footprint, now covering over 90% of the global rare disease market directly, with new organizations established in key markets like Japan, Korea, Australia, and Brazil [12][39] - The company anticipates that international business could exceed 20% of total revenue by 2030 [39] Commitment to Patients and Sustainability - Sobi ranked as the most reputable company in the rare disease space according to a survey of 518 patient organizations [47] - The company has set scientific-based targets to reduce its carbon footprint while increasing business operations [15][16] Research and Development - Sobi is currently running over 40 clinical trials globally, with a focus on regulatory approvals and scientific leadership [44][45] - The company has achieved 36 regulatory approvals in major markets over the past year, indicating strong growth potential [45][48] Financial Performance - Sobi's financial outlook remains positive, with expectations of sustained growth driven by new product launches and market expansion [3][24] Conclusion - Sobi is positioned for significant growth with a robust pipeline and strategic focus on rare diseases, aiming to double its size by 2030 while maintaining a commitment to patient care and sustainability [43][44]

Sobi Capital Markets Day 2026 18 February 2026 Forward-looking statements In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to the financial condition, results of operations and businesses of Swedish Orphan Biovitrum AB (publ), By their nature, forward-looking statements and forecasts invol ...

Summary of Swedish Orphan Biovitrum (Sobi) FY Conference Call Company Overview - **Company**: Swedish Orphan Biovitrum (Sobi) - **Date of Conference**: January 13, 2026 - **Key Speakers**: Guido Oelkers (CEO), Gerard Tobin (Head of IR) Core Industry Insights - **Strategic Portfolio Growth**: The strategic portfolio grew by 39%, now representing over 60% of total business [2][3] - **Acquisition of Arthrosi**: The acquisition of Arthrosi is aimed at strengthening the gout franchise, with expectations of significant growth potential and a long patent life [4][5] - **Pipeline Developments**: Positive readouts from the IDS (interferon gamma-driven sepsis) study, indicating a significant unmet medical need with a patient population of 1.5-2 million in Europe and the US [9][10] Financial Performance - **Q3 Performance**: Strong underlying growth reported in Q3, with a focus on the strategic portfolio [2][3] - **Market Share**: Over 60% market share in early launch countries for Altuviiio, with a shift in patient acquisition from competition [15] Product Launches and Expectations - **Upcoming Launches**: Multiple product launches scheduled, including: - **Altuviiio**: Ongoing launch in 20 countries, expected to remain a growth driver [6] - **SEL-212**: PDUFA date set for June 27, 2026, targeting chronic refractory gout [12] - **Gamifant**: Secondary HLH indication launch ongoing, with regulatory decisions expected in Japan [12] - **Tringold**: Launched for FCS indication, with further launches planned [7] - **AR882**: Expected launch in Q1 2028 [7] Regulatory and Market Strategy - **Regulatory Approvals**: Anticipated regulatory decisions for C3G/IC-MPGN in Europe and Japan [12] - **Market Positioning**: Strategic acquisition of Arthrosi ahead of phase 3 data to secure competitive advantage [16][17] Future Outlook - **Optimism for 2026**: The company expresses strong momentum and optimism for future growth, supported by a robust pipeline and strategic acquisitions [13][14] - **Beyfortus Development**: Continued commitment to Beyfortus for RSV prevention, with stable earning streams expected despite market debates [20][21][22] Additional Insights - **Focus on Unmet Needs**: Emphasis on addressing high unmet medical needs, particularly in sepsis and gout [9][10] - **Long-term Vision**: Plans to discuss future ambitions and product strategies at the upcoming Capital Markets Day [23] This summary encapsulates the key points discussed during the conference call, highlighting the company's strategic direction, product pipeline, and market positioning.